amphastar.com - רווח החברה לפני מסים, ריבית ופחת AMPH

Investments in complex biosimilar systems and innovative drug delivery are driving growth for Amphastar Pharmaceuticals (AMPH). The annual EBITDA figure on the GURU.Markets terminal chart confirms this potential, stabilizing at 208.48. Revenues are based on the sale of generics and emergency medical supplies. Stable demand for injectable drugs shields the company from economic cyclicality, ensuring the resilience of its financial results.

This indicator reflects the actual liquidity inflow from core operations, adjusted for the impact of taxes and debt obligations. By analyzing the consolidated EBITDA, an investor sees the actual speed of cash generation in a real-time assessment. The metric measures the efficiency of the operating cycle, excluding accounting distortions from depreciation. For Amphastar Pharmaceuticals (AMPH), this is critical during the transition from selling generics to implementing proprietary patented delivery systems. Steady growth in this line confirms the successful diversification of the business model.